Skip to main content
SpringerLink
Log in

Management of Juvenile Idiopathic Arthritis

  • Chapter
  • First Online:
Pediatric Rheumatology

Abstract

To learn about the guiding principles of management of juvenile idiopathic arthritis (JIA)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.

    PubMed  Google Scholar 

  2. Prakken BJ, Albani S. Using biology of disease to understand and guide therapy of JIA. Best Pract Res Clin Rheumatol. 2009;23:599–608.

    Article  CAS  PubMed  Google Scholar 

  3. Lin YT, Wang CT, Gershwin ME, Chiang BL. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev. 2011;10(8):482–9.

    Article  CAS  PubMed  Google Scholar 

  4. Aggarwal AMD. Enthesitis related arthritis. Clin Rheumatol. 2015;34:1839–46.

    Article  PubMed  Google Scholar 

  5. Beukelman T, Patkar NM, Saag KG, et al. American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–82.

    Article  Google Scholar 

  6. Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother. 2009;10:3049–60.

    Article  CAS  PubMed  Google Scholar 

  7. Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290–4.

    PubMed  Google Scholar 

  8. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al, for the Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–66.

    Google Scholar 

  9. Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity and acceptable symptom state in juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(7):2366–74. doi:10.1002/art.34373.

    Article  PubMed  Google Scholar 

  10. Bartoli M, Taro M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67:370–4.

    Article  CAS  PubMed  Google Scholar 

  11. Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE – JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70:1605–12.

    Article  PubMed  Google Scholar 

  12. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012–21. doi:10.1002/art.34343.2012.

    Article  PubMed  Google Scholar 

  13. Wallace CA, Ringold S, Bohnsack J, Spalding SJ, Brunner HI, Milojevic D, et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol. 2014;41(12):2459–65.

    Article  PubMed  Google Scholar 

  14. Kochar R, Walsh KM, Jain A, Spalding SJ, Hashkes PJ. Decreased use of non-steroidal anti-inflammatory drugs for the treatment of juvenile idiopathic arthritis in the era of modern aggressive treatment. Rheumatol Int. 2012;32(10):3055–60. doi:10.1007/s00296-011-2084-7.

    Article  CAS  PubMed  Google Scholar 

  15. Kahn P. Juvenile idiopathic arthritis – an update on pharmacotherapy. Bull NYU Hosp Jt Dis. 2011;69(3):264–76.

    PubMed  Google Scholar 

  16. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655–66.

    Article  CAS  PubMed  Google Scholar 

  17. Broughton T, Armon K. Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus. Paediatr Drugs. 2012;14(1):7–12.

    Article  PubMed  Google Scholar 

  18. Van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998;41:808–16.

    Article  PubMed  Google Scholar 

  19. Van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007;66:1518–24.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, Hernandez–Garduno A, Goycochea-Robles MV. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61:941–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Allaart CF, Breedveld FC, Dijkmans BA. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol Suppl. 2007;80:25–33.

    CAS  PubMed  Google Scholar 

  22. Beresford MW, Baildam EM. New advances in the management of juvenile idiopathic arthritis–1: non-biological therapy. Arch Dis Child Educ Pract Ed. 2009;94:144–50.

    Article  CAS  PubMed  Google Scholar 

  23. Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012;39(9):1867–74.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20.

    Article  CAS  PubMed  Google Scholar 

  25. Ruperto N, Lovell D, Reiff A, Gamir M, Higgins G, Koné-Paut I, et al. Long-term efficacy and safety of adalimumab in 4–12 year old patients with juvenile idiopathic arthritis. Pediatric Rheumatology. 2011;9 Suppl 1:O26.

    Article  PubMed Central  Google Scholar 

  26. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763–9.

    Article  CAS  PubMed  Google Scholar 

  27. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496–504.

    Article  CAS  PubMed  Google Scholar 

  28. Chang CY, Meyer RM, Reiff AO. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res (Hoboken). 2015;67(5):658–66.

    Article  CAS  Google Scholar 

  29. Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73(6):1114–22.

    Article  CAS  PubMed  Google Scholar 

  30. Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I, et al. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016;43(4):816–24.

    Article  PubMed  Google Scholar 

  31. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011;50(1):214–21.

    Article  CAS  Google Scholar 

  32. Ruperto N, Lovell D, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096–106.

    Article  CAS  PubMed  Google Scholar 

  33. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383–91.

    Article  CAS  PubMed  Google Scholar 

  34. Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:1792–802.

    Article  CAS  PubMed  Google Scholar 

  35. Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken). 2013;65(10):1551–63.

    Article  Google Scholar 

  36. Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2011. doi:10.1007/s10165-011-0481-0.

    Google Scholar 

  37. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.

    Article  CAS  PubMed  Google Scholar 

  38. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1163–72.

    Article  PubMed  Google Scholar 

  39. Kasher-Meron M, Uziel Y, Amital H. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report. Rheumatol Oxf. 2009;48:445–66.

    Article  Google Scholar 

  40. Dörner TKJ. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11(12):713–24.

    Article  PubMed  Google Scholar 

  41. Yoo DH PN, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-2015-208786

  42. Park W YD, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-2015-208783.

  43. Ringold S, Weiss PF, Colbert RA, DeWitt EM, Lee T, Onel K, et al. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2014;66(7):1063–72.

    Article  Google Scholar 

  44. https://www.engage.england.nhs.uk/consultation/specialised-servicespolicies/user_uploads/biolgcs-juvenl-idiop-arthrs-pol.pdf. ENICCPSBTfttoJIAJAf.

  45. Hashkes PJ. Strengths and challenges of a new guide for treating JIA. Nat Rev Rheumatol. 2011;7(7):377–8.

    Article  PubMed  Google Scholar 

  46. Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005;52(2):563–72.

    Article  CAS  PubMed  Google Scholar 

  47. Sobel RE, Lovell DJ, Brunner HI, Weiss JE, Morris PW, Gottlieb BS, et al. Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry. Pediatr Rheumatol Online J. 2014;12:29.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum. 1999;42:2330–4.

    Article  CAS  PubMed  Google Scholar 

  49. Marti P, Molinari L, Bolt IB, Seger R, Saurenmann RK. Factors influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis. Eur J Pediatr. 2008;167:425–30.

    Article  PubMed  Google Scholar 

  50. Dore RK. Clinical utility of etanercept in the treatment of arthritides in children and adolescents. Adolesc Health Med Ther. 2014;5:35–48.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol. 2014;66(9):2580–9.

    Article  CAS  PubMed  Google Scholar 

  52. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110–7.

    Article  PubMed  Google Scholar 

  53. Webb K, Wedderburn LR. Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol. 2015;27(5):505–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Chickermane PR, Khubchandani RP. Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate. Clin Exp Rheumatol. 2015;33(2):287–92.

    PubMed  Google Scholar 

  55. Weiss PF. Evaluation and treatment of enthesitis-related arthritis. Curr Med Lit Rheumatol. 2013;32(2):33–41.

    PubMed  PubMed Central  Google Scholar 

  56. Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis–data from the Dutch arthritis and biologicals in children register, 1999–2010. J Rheumatol. 2011;38:2258–63.

    Article  CAS  PubMed  Google Scholar 

  57. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014;12:13.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Onel K, Prahalad S, Schneider R, Stoll ML. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthrit Care Res. 2012. Doi: 10.100:1–36.

    Google Scholar 

  59. Woerner A, Uettwiller F, Melki I, Mouy R, Wouters C, Bader-Meunier B, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015;1(1), e000036.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Kasapcopur O, Barut K. Treatment in juvenile rheumatoid arthritis and new treatment options. Turk Pediatri Ars. 2015;50(1):1–10.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, Cohen N, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55(4):669–79.

    Article  Google Scholar 

  62. Sauberan DP. Pediatric uveitis. Intern Ophth Clin. 2010;50(4):73–85.

    Article  Google Scholar 

  63. Rabinovich CE. Treatment of juvenile idiopathic arthritis associated uveitis: challenges and update. Curr Opin Rheumatol. 2011;23:432–6.

    Article  CAS  PubMed  Google Scholar 

  64. Wentworth BA, Freitas-Neto CA, Foster CS. Management of pediatric uveitis. F1000Prime Rep. 2014;6:41.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Semeraro F, Arcidiacono B, Nascimbeni G, Angi M, Parolini B, Costagliola C. Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis. Drug Des Devel Ther. 2014;8:341–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Garcia-De-Vicuna C, Diaz-Llopis M, Salom D, Bou R, Diaz-Cascajosa J, Cordero-Coma M, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:560632.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Henderson LA, Zurakowski D, Angeles-Han ST, Lasky A, Rabinovich CE, Lo MS. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2016;14(1):9.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303:1266–73.

    Article  CAS  PubMed  Google Scholar 

  69. Foell D, Frosch M, Schulze zur Wiesch A, Vogl T, Sorg C, Roth J. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis. 2004;63:206–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Bernatsky S, Rosenberg AM, Oen KG, et al. Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol. 2011;38:760–3.

    Article  PubMed  Google Scholar 

  71. Quartier P. Current treatments for juvenile idiopathic arthritis. Joint Bone Spine. 2010;77(6):511–6.

    Article  CAS  PubMed  Google Scholar 

  72. Thompson S, Barnes M, Griffin T, Grom A, Glass DN. Heterogeneity in JIA, impact of molecular profiling based on DNA polymorphism and gene expression patterns. Arthritis Rheum. 2010;62:2611–5.

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

This chapter has been modified and updated (With permission) from a previous publication: Sawhney S, Juvenile idiopathic arthritis: Classification, clinical features, and management. Indian Journal of Rheumatology 2012;7 (1) 11-21.

Author information

Authors and Affiliations

  1. Division of Pediatric Rheumatology, Institute of Child Health, Sir Ganga Ram Hospital, New Delhi, India

    Sujata Sawhney & Abhay Shivpuri

  2. Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Amita Aggarwal

Authors
  1. Sujata Sawhney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abhay Shivpuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amita Aggarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sujata Sawhney .

Editor information

Editors and Affiliations

  1. Pediatric Rheumatology Division Institute of Child Health, Sir Ganga Ram Hospital, New Delhi, India

    Sujata Sawhney

  2. Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Amita Aggarwal

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Sawhney, S., Shivpuri, A., Aggarwal, A. (2017). Management of Juvenile Idiopathic Arthritis. In: Sawhney, S., Aggarwal, A. (eds) Pediatric Rheumatology. Springer, Singapore. https://doi.org/10.1007/978-981-10-1750-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-1750-6_20

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-1749-0

  • Online ISBN: 978-981-10-1750-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation